Can we predict who will benefit from immunotherapy? new study aims to find out.

NCT ID NCT07147361

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both past and future, to develop a scoring system. The goal is to help doctors choose the right treatment for the right patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PD-1 inhibitor (with or without chemotherapy)
What this could lead to
If successful, this could help doctors predict which patients with squamous cell carcinoma will benefit from PD-1 inhibitors, leading to more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial. The biomarkers identified may not prove useful in practice, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Etiology and Carcinogenesis

    Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.